Clinical Efficacy of Kaishore Guggulu and Balaguduchyadi Taila in the Management of Gout (Vatarakta)

CCRAS0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Primary Gouty arthritis fulfilling the diagnostic criteria as recommended by the American College of Rheumatology (1977), it should meet the presence of any six of the following twelve criteria:
•i. More than one attack of acute arthritis.
•ii. Maximal inflammation developing within 1 day of onset.
•iii. Monoarthritis attack
•iv. Redness over affected joint
•v. Unilateral attack on the first Metatarsophalangeal (Big Toe) joint.
•vi. Unilateral attack involving Tarsal joint.
•vii. First Metatarsophalangeal (Big Toe) joint Painful or Swollen.
•viii. Suspected Tophi
•ix. Hyperuricemia (equal or more than 7.0 mg/dl)
•x. Asymmetrical swelling within joint (X Ray)
•xi. Sub cortical cysts without erosion (X Ray)
•xii. Negative culture from joint fluid during attack.
•Though mentioned as one of the criteria, no synovial fluid examination will be carried out. Diagnosis will be made out of eleven ACR criteria
•2. Willing and able to participate in the study for 14 weeks.

•1. Age less than 18 yrs or more than 65yrs.
•2. History of any trauma/ fractured joint/ surgical/diagnostic intervention with reference to the affected joint(s).
•3. Patients with co-morbidities such as Rheumatoid arthritis, Psoriatic arthritis etc.
•4. Patients with poorly controlled Hypertension (equal or more than 160/100 mm of Hg).
•5. Patients with poorly controlled Diabetes Mellitus (HbA1c equal or more than 8.0%)
•6. Patients with evidence of malignancy.
•7. Patients with unstable cardio-vascular disease.
•8. Patients with hypothyroidism having TSH level more than 10mlU/lit and known cases of hyperthyroidism.
•9. Patients with any concurrent hepatic disorder (defined as liver enzymes SGOT/SGPT more than 2 times of upper normal limit) or Renal Disorders (defined as S.Creatinine more than 1.4mg/dl) or Severe COPD.
•10. Alcoholics/drug abusers.
•11. H/o hypersensitivity to any of the trial drugs or their ingredients.
•12. Pregnant/lactating woman.
•13. Any other condition which the Principal Investigator thinks may jeopardize the study.

发起方

CCRAS